نتائج البحث - Geneviève Legault

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    <i>BRAF</i>Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549

    <i>BRAF</i>Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549 حسب Alex Y. Lin, Fausto J. Rodríguez, Matthias A. Karajannis, Susan Williams, Geneviève Legault, David Zagzag, Peter C. Burger, Jeffrey C. Allen, Charles G. Eberhart, Eli E. Bar

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

    Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas حسب Matthias A. Karajannis, Geneviève Legault, Mari Hagiwara, Marc Ballas, Krysten Brown, Annette O. Nusbaum, Tsivia Hochman, Judith D. Goldberg, Kevin M. Koch, John G. Golfinos, J. Thomas Roland, Jeffrey C. Allen

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

    Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas حسب Matthias A. Karajannis, Geneviève Legault, Mari Hagiwara, Filippo G. Giancotti, Alexander S. Filatov, Anna Derman, Tsivia Hochman, Judith D. Goldberg, Emilio Vega-Gonzales, Jeffrey H. Wisoff, John G. Golfinos, Amanda Merkelson, J. Thomas Roland, Jeffrey C. Allen

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01 حسب Sébastien Perreault, Valérie Larouche, Uri Tabori, Cynthia Hawkin, Sarah Lippé, Benjamin Ellezam, Jean‐Claude Décarie, Yves Théorêt, Marie‐Élaine Métras, Serge Sultan, Édith Cantin, Marie-Ève Routhier, Maxime Caru, Geneviève Legault, Éric Bouffet, Lucie Lafay‐Cousin, Juliette Hukin, Craig Erker, Nada Jabado

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

    Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas حسب Matthias A. Karajannis, Geneviève Legault, Michael J. Fisher, Sarah Sarvis Milla, Kenneth J. Cohen, Jeffrey H. Wisoff, D. H. Harter, Judith D. Goldberg, T. Hochman, Amanda Merkelson, Michael Bloom, A. J. Sievert, Adam Resnick, Girish Dhall, David Jones, Andrey Korshunov, Stefan M. Pfister, Charles G. Eberhart, David Zagzag, Jeffrey C. Allen

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: